PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis

Peng,Fang; Li,Qiang; Sun,Jia-Yuan; Luo,Ying; Chen,Ming; Bao,Yong

doi:10.3892/ijo.2018.4257

PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis

Authors:
- Fang Peng
- Qiang Li
- Jia-Yuan Sun
- Ying Luo
- Ming Chen
- Yong Bao
View Affiliations

Affiliations: Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, P.R. China, Department of Clinical Laboratory, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China, Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang 310022, P.R. China
Published online on: January 30, 2018 https://doi.org/10.3892/ijo.2018.4257
Pages: 945-954

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

6-Phosphofructo 2-kinase/fructose 2, 6-bisphosphatase 3 (PFKFB3) has been reported to be overexpressed in human cancer tissues and to promote the proliferation and migration of cancer cells. However, the role of PFKFB3 in the progression and prognosis of breast cancer is not yet fully understood. In the present study, we investigated the specific role of PFKFB3 in breast cancer progression and its preliminary mechanisms of action. We first used an immunohistochemistry assay to determine that PFKFB3 was highly expressed in breast cancer tissues and that this high level of expression was involved in the poor overall survival of patients with breast cancer. In addition, the suppression of PFKFB3 by lentiviruses carrying shRNA against PFKFB3 (shPFKFB3) subsequently inhibited breast cancer cell (MDA-MB-231 and MDA-MB-468) proliferation, migration and invasion, and induced cell cycle G1 and S phase arrest in vitro. Moreover, PFKFB3 inhibition decreased p-AKT and increased p27 expression levels in breast cancer cells. Furthermore, PFKFB3 suppression inhibited breast cancer cell tumor xenograft growth in nude mice. We also found that PFKFB3 inhibition suppressed vascular endothelial growth factor α (VEGFα) protein expression and inhibited the angiogenic activity of human umbilical vein endothelial cells (HUVECs). On the whole, our results indicate that PFKFB3 is involved in the proliferation, migration, invasion and angiogenesis of breast cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A and Muñoz M: Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 24(Suppl 2): S26–S35. 2015. View Article : Google Scholar : PubMed/NCBI
3	Kocemba KA, Dulińska-Litewka J, Wojdyła KL and Pękala PA: The role of 6-phosphofructo-2-kinase (PFK-2)/fructose 2,6-bisphosphatase (FBPase-2) in metabolic reprogramming of cancer cells. Postepy Hig Med Dosw. 70:938–950. 2016. View Article : Google Scholar
4	Yalcin A, Telang S, Clem B and Chesney J: Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphos-phatases in cancer. Exp Mol Pathol. 86:174–179. 2009. View Article : Google Scholar : PubMed/NCBI
5	Okar DA, Manzano A, Navarro-Sabatè A, Riera L, Bartrons R and Lange AJ: PFK-2/FBPase-2: Maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci. 26:30–35. 2001. View Article : Google Scholar : PubMed/NCBI
6	Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG and Hue L: 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-tase: Head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J. 381:561–579. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kim SG, Manes NP, El-Maghrabi MR and Lee YH: Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A possible new target for cancer therapy. J Biol Chem. 281:2939–2944. 2006. View Article : Google Scholar
8	Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA II, Klarer AC, Redman R, Miller DM, Trent JO, et al: Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 12:1461–1470. 2013. View Article : Google Scholar : PubMed/NCBI
9	Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 62:5881–5887. 2002.PubMed/NCBI
10	O'Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J and Clem BF: Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2⁺ breast cancer. Breast Cancer Res Treat. 160:29–40. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W and Gu Y: Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochem Biophys Res Commun. 463:1115–1121. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hu KY, Wang G, Liu PF, Cao YW, Wang YH, Yang XC, Hu CX, Sun LJ and Niu HT: Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment. Oncol Rep. 36:945–951. 2016. View Article : Google Scholar : PubMed/NCBI
13	Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X, Kandala S, Li Q, Li H, Zhang C, et al: Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler Thromb Vasc Biol. 34:1231–1239. 2014. View Article : Google Scholar : PubMed/NCBI
14	Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, et al: PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 110:923–932. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kim JW and Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930. 2006. View Article : Google Scholar : PubMed/NCBI
16	Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, et al: Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 19:37–48. 2014. View Article : Google Scholar
17	Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ and Verheij M: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs. 14:167–173. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
19	Qu J, Lu D, Guo H, Miao W, Wu G and Zhou M: PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage. Clin Exp Pharmacol Physiol. 43:312–318. 2016. View Article : Google Scholar : PubMed/NCBI
20	Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008. View Article : Google Scholar : PubMed/NCBI
21	Slingerland J and Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 183:10–17. 2000. View Article : Google Scholar : PubMed/NCBI
22	Calvo MN, Bartrons R, Castaño E, Perales JC, Navarro-Sabaté A and Manzano A: PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett. 580:3308–3314. 2006. View Article : Google Scholar : PubMed/NCBI
23	Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S and Chesney J: 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 5:e13372014. View Article : Google Scholar : PubMed/NCBI
24	Wagner KD, Cherfils-Vicini J, Hosen N, Hohenstein P, Gilson E, Hastie ND, Michiels JF and Wagner N: The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression. Nat Commun. 5:58522014. View Article : Google Scholar : PubMed/NCBI
25	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
26	Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar : PubMed/NCBI
27	Yan F, Tan XY, Geng Y, Ju HX, Gao YF and Zhu MC: Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth. Cancer Biother Radiopharm. 26:183–189. 2011. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔC_T Method. Methods. 25:402–408. 2001. View Article : Google Scholar
29	Matsui TA, Murata H, Sowa Y, Sakabe T, Koto K, Horie N, Tsuji Y, Sakai T and Kubo T: A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells. Oncol Rep. 24:329–333. 2010.PubMed/NCBI
30	Bouïs D, Hospers GA, Meijer C, Molema G and Mulder NH: Endothelium in vitro: A review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 4:91–102. 2001. View Article : Google Scholar
31	Lau WH, Pandey V, Kong X, Wang XN, Wu Z, Zhu T and Lobie PE: Trefoil factor-3 (TFF3) stimulates de novo angiogenesis in mammary carcinoma both directly and indirectly via IL-8/CXCR2. PLoS One. 10:e01419472015. View Article : Google Scholar : PubMed/NCBI
32	Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL and Teicher BA: Endothelial precursor cells as a model of tumor endothelium: Characterization and comparison with mature endothelial cells. Cancer Res. 63:5866–5873. 2003.PubMed/NCBI
33	Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A and Esumi H: Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World J Gastroenterol. 20:13705–13717. 2014. View Article : Google Scholar : PubMed/NCBI
34	Chesney J: 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-tase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care. 9:535–539. 2006. View Article : Google Scholar : PubMed/NCBI
35	Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han JH, Metz C and Bucala R: An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci USA. 96:3047–3052. 1999. View Article : Google Scholar : PubMed/NCBI
36	Minchenko OH, Ogura T, Opentanova IL, Minchenko DO, Ochiai A, Caro J, Komisarenko SV and Esumi H: 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor. Ukr Biokhim Zh (1999). 77:46–50. 2005.
37	Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV and Esumi H: Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie. 87:1005–1010. 2005. View Article : Google Scholar : PubMed/NCBI
38	Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, et al: Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem. 284:24223–24232. 2009. View Article : Google Scholar : PubMed/NCBI
39	Doménech E, Maestre C, Esteban-Martínez L, Partida D, Pascual R, Fernández-Miranda G, Seco E, Campos-Olivas R, Pérez M, Megias D, et al: AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol. 17:1304–1316. 2015. View Article : Google Scholar : PubMed/NCBI
40	Clem B, Telang S, Clem A, Goswami U and Chesney J: Inhibition of 6-phosphofructo-2-kinase suppresses breast tumor growth in vivo. Cancer Res. 69(2 Suppl): 30642009. View Article : Google Scholar
41	Han J, Meng Q, Xi Q, Wang H and Wu G: PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells. Cancer Biomark. 18:249–256. 2017. View Article : Google Scholar
42	Bobarykina AY, Minchenko DO, Opentanova IL, Moenner M, Caro J, Esumi H and Minchenko OH: Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers. Acta Biochim Pol. 53:789–799. 2006.PubMed/NCBI
43	Ge X, Cao Z, Gu Y, Wang F, Li J, Han M, Xia W, Yu Z and Lyu P: PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production. Cell Mol Biol (Noisy-le-Grand, France). 62:119–125. 2016.
44	Lu L, Chen Y and Zhu Y: The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget. 8:62793–62802. 2017.PubMed/NCBI
45	Møller MB: P27 in cell cycle control and cancer. Leuk Lymphoma. 39:19–27. 2000. View Article : Google Scholar : PubMed/NCBI
46	Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, et al: Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. 34:5447–5459. 2015. View Article : Google Scholar : PubMed/NCBI
47	Simon-Molas H, Nieves Calvo-Vidal M, Castaño E, Bartrons R and Manzano A: Akt mediates TIGAR induction in HeLa cells following PFKFB3 inhibition. FEBS Lett. 17:pp. 59020162016, https://doi.org/10.1002/1873-3468.12338.
48	Rodríguez-García A, Samsó P, Fontova P, Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martinez-Outshoorn U, Ventura F, Navarro-Sabaté À, et al: TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. FEBS J. 284:3437–3454. 2017. View Article : Google Scholar
49	Guo C, Buranych A, Sarkar D, Fisher PB and Wang XY: The role of tumor-associated macrophages in tumor vascularization. Vasc Cell. 5:202013. View Article : Google Scholar : PubMed/NCBI
50	Zhang LZ, Zhang CQ, Yan ZY, Yang QC, Jiang Y and Zeng BF: Tumor-initiating cells and tumor vascularization. Pediatr Blood Cancer. 56:335–340. 2011. View Article : Google Scholar : PubMed/NCBI
51	Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, Chaturvedi P, Hol J, Thienpont B, Teuwen LA, et al: Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell. 30:968–985. 2016. View Article : Google Scholar : PubMed/NCBI